Note: Please print this page and use it as a cover sheet. Type the fax audit number (shown below) on the top and bottom of all pages of the document.

(((H23000282044 3)))



H230002820443ABCZ

Note: DO NOT hit the REFRESH/RELOAD button on your browser from this page. Doing so will generate another cover sheet.

To:

Division of Corporations

Fax Number

: (850)617-6380

From:

Account Name : NASON, YEAGER, GERSON, WHITE & LIOCE, P.A.

Account Number : 073222003555 Phone : (561)686-3307 Fax Number : (561)290-1590

Enter the email address for this business entity to be used for future annual report mailings. Enter only one email address please.


Email Address: randybeimel@gmail.com

COR AMND/RESTATE/CORRECT OR O/D RESIGN REGENERATIVE MEDICINE ORTHOPAEDIC SOCIETY INC.

Certificate of Status	1
Certified Copy	0
Page Count	05
Estimated Charge	\$43.75

Electronic Filing Menu

Corporate Filing Menu



15619488372

PREFERENCES AND RIGHTS OF SERIES B CONVERTIBLE PREFERRED STOCK

The undersigned President of Regenerative Medicine Orthopaedic Society Inc. (the "Corporation"), a company organized and existing under the laws of the State of Florida, certifies that pursuant to the authority contained in the Corporation's Articles of Incorporation, and in accordance with the provisions of the resolution creating a series of the class of the Corporation's authorized Preferred Stock designated as Series A Convertible Preferred Stock:

FIRST: The Articles of Incorporation of the Corporation bearing document number P23000002092 authorizes the issuance of one hundred eighty million (180,000,000) shares of common stock, par value \$0.0001 per share (the "Common Stock") and twenty million (20,000,000) shares of preferred stock (the "Preferred Stock") of which six (6,000,000) million shares are designated Series A Convertible Preferred stock, and further, authorizes the Board of Directors of the Corporation, by resolution or resolutions, at any time and from time to time, to divide and establish any or all of the shares of Preferred Stock into one or more series and, without limiting the generality of the foregoing, to fix and determine the designation of each such share, and its preferences, conversion rights, cumulative, relative, participating, optional, or other rights, including voting rights, qualifications, limitations, or restrictions thereof.

SECOND: Pursuant to a unanimous written consent of the Board of Directors, dated July ___, 2023, the directors unanimously approved the designation of Series B Preferred Stock. The designations, powers, preferences and rights, and the qualifications, limitations or restrictions hereof, in respect of the Series B. Convertible Preferred Stock shall be as hereinafter described.

Accordingly, "Article IV" of the Articles of Incorporation of this Corporation is amended to include the following:

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock.

- 1. Designation and Number of Shares. There shall be series of Preferred Stock that shall be designated as "Series B Convertible Preferred Stock", and the number of shares constituting such series shall be Ten Million Five Hundred Thousand (10,500,000) shares. The price per share shall be \$0.0001 per share (the "Original Issuance Price"). Such number of shares may be increased or decreased by resolution of the Board of Directors; provided, however, that no decrease shall reduce the number of shares of Series B Convertible Preferred Stock to less than the number of shares then issued and outstanding plus the number of shares issuable upon exercise of outstanding rights, options or warrants or upon conversion of outstanding securities issued by the Corporation.
- 2. Ranking. The Series B Convertible Preferred Stock shall rank on parity with the Corporation's Series A Convertible Preferred Stock and Common Stock and any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms on parity with the Series B Convertible Preferred Stock (the "Parity Securities"), in each case as to the distribution of assets upon liquidation, dissolution or winding up of this Corporation.

3. <u>Liquidation</u>. Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary ("Liquidation"), the holders of record of the shares of the Series B Convertible Preferred Stock shall be entitled to receive assets and funds on parity with the Parity Securities. If, upon such Liquidation, the assets of the Corporation available for distribution to the holders of Series B Convertible Preferred Stock and any Parity Securities shall be insufficient to permit payment in full to the holders of the Series B Convertible Preferred Stock and Parity Securities, then the entire assets and funds of the Corporation legally available for distribution to such holders and the holders of the Parity Securities then outstanding shall be distributed ratably among the holders of the Series B Convertible Preferred Stock and Parity Securities based upon the proportion the total amount distributable on each share upon Liquidation bears to the aggregate amount required to be distributed, but for the provisions of this sentence, on all shares of the Series B Convertible Preferred Stock and of such Parity Securities, if any.

4. Dividends.

None.

5. Conversion Rights.

(a) <u>Conversion</u>.

- Voluntary Conversion. Each holder of record of shares of the Series B Convertible Preferred Stock shall have the right to convert all or any part of such holder's shares of Series B Convertible Preferred Stock into that number of fully paid and non-assessable shares of Common Stock as shall be determined by dividing the Original Issuance Price by the "Conversion Price". The Conversion Price shall initially be \$0.00002 per share and shall be subject to adjustment as provided below.
- (ii) Mandatory Conversion. Upon either (A) the closing of the sale of shares of Common Stock to the public, in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, or (B) consent of the Board of Directors, the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the "Mandatory Conversion Time"; then (x) all outstanding shares of Series B Convertible Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective Conversion Price as calculated pursuant to Section 5(a)(i), and (y) such shares of Series B Preferred Stock may not be reissued by the Corporation. All holders of record of shares of Series B Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Series B Preferred Stock pursuant to this Section 5(a)(ii). Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time.

(b) Mechanics of Conversion.

(i) Conversion shall be deemed to have been effected on the date when delivery of notice of an election to convert and certificates for shares is made under Section 5(a)(i) or the Mandatory Conversion Time. At the option of the Corporation, before any holder of Series B Convertible Preferred Stock shall be entitled to convert the same into shares of Common Stock, such holder shall surrender the

2

16476-32550 / 01597327 v1

certificate or certificates therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the Series B Convertible Preferred Stock, and shall give written notice to the Corporation at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates for shares of Common Stock are to be issued. The Corporation shall, within five business days, issue and deliver at such office to such holder of Series B Convertible Preferred Stock, or to the nominee or nominees of such holder, a certificate or certificates for the number of shares of Common Stock to which such holder shall be entitled as aforesaid.

- (ii) All Common Stock, which may be issued upon conversion of the Series B Convertible Preferred Stock, will, upon issuance, be duly issued, fully paid and non-assessable and free from all taxes, liens, and charges with respect to the issuance thereof. Such converted Series B Convertible Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Series B Preferred Stock accordingly.
- (c) <u>Conversion Price Adjustments.</u> The Conversion Price shall be subject to the adjustment provisions of Section 6 below.
- 6. Adjustment Provisions. During the period in which any shares of Series B Convertible Preferred Stock remain outstanding, the Conversion Price in effect at any time and the number and kind of securities issuable upon the conversion of the Series B Convertible Preferred Stock shall be subject to adjustment from time to time following the date of the original issuance of the Series B Convertible Preferred Stock upon the happening of certain events as follows:
 - (a) Consolidation, Merger or Sale. If any consolidation or merger of the Corporation with an unaffiliated third-party, or the sale, transfer or lease of all or substantially all of its assets to an unaffiliated third-party shall be effected in such a way that holders of shares of Common Stock shall be entitled to receive stock, securities or assets with respect to or in exchange for their shares of Common Stock, then provision shall be made, in accordance with this Section 6(a), whereby each holder of shares of Series B Convertible Preferred Stock shall thereafter have the right to receive such securities or assets as would have been issued, or payable with respect to or in exchange for the shares of Common Stock into which the shares of Series B Convertible Preferred Stock held by such holder were convertible immediately prior to the closing of such merger, sale, transfer or lease, as applicable. The Corporation will not effect any such consolidation, merger, sale, transfer or lease unless prior to the consummation thereof the successor entity (if other than the Corporation) resulting from such consolidation or merger or the entity purchasing or leasing such assets shall assume by written instrument (i) the obligation to deliver to the holders of Series B Convertible Preferred Stock such securities or assets as, in accordance with the foregoing provisions, such holders may be entitled to purchase, and (ii) all other obligations of the Corporation hereunder. The provisions of this Section $\theta(a)$ shall similarly apply to successive mergers, sales, transfers or leases. Holder shall not be required to convert Series B Convertible Preferred Stock pursuant to this Section 6(a).
 - (b) <u>Common Stock Dividends, Subdivisions, Combinations, etc.</u> In case the Corporation shall hereafter (i) declare a dividend or make a distribution on its outstanding shares of Common Stock in shares of Common Stock, (ii) subdivide or reclassify its outstanding shares of

Common Stock into a greater number of shares, or (iii) combine or reclassify its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect at the time of the record date for such dividend or distribution or of the effective date of such subdivision, combination or reclassification shall be adjusted by multiplying the then applicable Conversion Price by a fraction, the denominator of which shall be the number of shares of Common Stock outstanding after giving effect to such action, and the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such action. Such adjustment shall be made successively whenever any event listed above shall occur.

- Notice of Adjustments. Whenever the Conversion Price is adjusted as herein provided, the Corporation shall promptly but no later than 10 days after any request for such an adjustment by the holder, cause a notice setting forth the adjusted Conversion Price issuable upon exercise of each share of Series B Convertible Preferred Stock, and, if requested, information describing the transactions giving rise to such adjustments, to be mailed to the holders at their last addresses appearing in the share register of the Corporation, and shall cause a certified copy thereof to be mailed to its transfer agent, if any. The Corporation may retain a firm of independent certified public accountants selected by the Board of Directors (who may be the regular accountants employed by the Corporation) to make any computation required by this Section 6, and a certificate signed by such firm shall be conclusive evidence of the correctness of such adjustment.
- 7. <u>Voting Right</u>. Each share of Series B Convertible Preferred Stock shall vote on a five-for-one (5 for 1) basis, together with the Corporation's Common Stock on all matters requiring shareholder approval under the Florida Business Corporation Act (except as otherwise required under the Florida Business Corporation Act). For clarification purposes, each share of Series B Convertible Preferred Stock shall vote five (5) times per share for every one vote of outstanding share of Common Stock, subject to the adjustment provisions of Section 6 above.
- 8. Redemption. Neither the Corporation nor the holders of the Series B Convertible Preferred Stock shall have any right at any time to require the redemption of any of the shares of Series B Convertible Preferred Stock, except upon and by reason of any liquidation, dissolution or winding-up of the Corporation, as and to the extent herein provided.
- Peservation of Shares. The Corporation shall at all times reserve and keep available and free of preemptive rights out of its authorized but unissued Common Stock, solely for the purpose of effecting the conversion of the Series B Convertible Preferred Stock pursuant to the terms hereof, such number of its shares of Common Stock (or other shares or other securities as may be required) as shall from time to time be sufficient to effect the conversion of all outstanding Series B Convertible Preferred Stock pursuant to the terms hereof. If at any time the number of authorized but unissued shares of Common Stock (or such other shares or other securities) shall not be sufficient to affect the conversion of all then outstanding Series B Convertible Preferred Stock, the Corporation shall promptly take such action as may be necessary to increases its authorized but unissued Common Stock (or other shares or other securities) to such number of shares as shall be sufficient for such purpose.

Miscellaneous.

(a) The shares of the Series B Convertible Preferred Stock shall not have any preferences, voting powers or relative, participating, optional, preemptive or other special rights except

- as set forth above in this Series B Convertible Preferred Stock Designation and in the Amended and Restated Articles of Incorporation of the Corporation.
- The holders of the Series B Convertible Preferred Stock shall be entitled to receive all (b) communications sent by the Corporation to the holders of the Common Stock.
- Subject to the approval of the Board of Directors of the Corporation, holders of fifty-one (c) percent (51%) of the outstanding shares of Series B Convertible Preferred Stock may, voting as a single class, elect to waive or amend any provision of this Designation of Series B Convertible Preferred Stock, and the affirmative vote of such percentage with respect to any proposed waiver or amendment of any of the provisions contained herein shall bind all holders of Series B Convertible Preferred Stock.

The foregoing Amendment was adopted by the Board of Directors of the Corporation pursuant to the Florida Business Corporation Act on July 5, 2023. Therefore, the number of votes east for the Amendment to the Corporation's Articles of incorporation was sufficient for approval.

IN WITNESS WHEREOF, the Corporation has caused this Amendment to be executed by Its duly authorized officer.

Dated: July 5., 2023

Regenerative Medicine Orthopaedic Society Inc.

By: Tahsin Beyzadeoglu, President